Hyperopic LASEK treatments with mitomycin C using the SCHWIND AMARIS

J Refract Surg. 2011 May;27(5):380-3. doi: 10.3928/1081597X-20101104-01. Epub 2010 Nov 5.

Abstract

Purpose: To investigate the outcomes of hyperopic laser epithelial keratomileusis (LASEK) with mitomycin C (MMC) using the SCHWIND AMARIS platform.

Methods: Prospective study of 28 eyes of 14 patients. Mean preoperative manifest spherical equivalent refraction was +2.71±0.72 diopters (D) (range: +1.50 to +4.50 D). All eyes underwent LASEK with an Aberration-Free™ algorithm with the SCHWIND AMARIS followed by a 35-second application of MMC with a 6.7-mm optical zone size.

Results: At 1 year, mean manifest spherical equivalent refraction was 0.03±0.30 D (range: -0.53 to +0.50 D), with 13 eyes within -0.13 to +0.13 D and all 28 eyes within ±0.50 D. Mean uncorrected distance visual acuity was -0.03±0.09 logMAR, and the efficacy and safety indices were 1, respectively, at 1 year. The postoperative manifest spherical equivalent refraction was stable between 1 and 3 months and 1 year.

Conclusions: Hyperopic LASEK with MMC using the SCHWIND AMARIS provided good outcomes in terms of accuracy, efficacy, safety, and stability.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Epithelium, Corneal / drug effects
  • Epithelium, Corneal / surgery*
  • Equipment Design
  • Follow-Up Studies
  • Glucocorticoids / administration & dosage*
  • Humans
  • Hyperopia / drug therapy
  • Hyperopia / physiopathology
  • Hyperopia / surgery*
  • Intraoperative Period
  • Keratectomy, Subepithelial, Laser-Assisted / instrumentation*
  • Middle Aged
  • Mitomycin / administration & dosage*
  • Ophthalmic Solutions
  • Prospective Studies
  • Refraction, Ocular
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Ophthalmic Solutions
  • Mitomycin